Slc17a9-KO Mouse
一般名
Slc17a9-KO
製品ID
S-KO-06223
背景情報
C57BL/6NCya
系統ID
KOCMP-228993-Slc17a9-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Slc17a9-KO Mouse（カタログ番号S-KO-06223）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Slc17a9-KO
系統ID
KOCMP-228993-Slc17a9-B6N-VA
遺伝子名
製品ID
S-KO-06223
遺伝子別名
Vnut, 1700019H03Rik
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conventional knockout
染色体
Chr 2
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000094218
NCBIトランスクリプトID
NM_183161
ターゲット領域
Exon 2~12
有効領域の大きさ
~8.9 kb
遺伝子研究の概要
Slc17a9, also known as VNUT (vesicular nucleotide transporter), functions as an ATP transporter in lysosomes and other secretory vesicles [5]. It is involved in multiple biological processes, such as regulating osteoblast differentiation [8], and may participate in pathways like the PI3K/Akt signaling pathway [7]. Dysregulation of Slc17a9 has been linked to various diseases, highlighting its biological importance.
In cancer research, knockdown of Slc17a9 in renal cancer cells inhibited their proliferation, migration, and invasion, while overexpression led to a more malignant phenotype both in vitro and in vivo, suggesting its role in promoting the progression of clear cell renal cell carcinoma through the SLC17A9-PTHLH-EMT axis [1]. In hepatocellular carcinoma, HHEX-mediated ABI2 upregulated Slc17a9 to promote cancer stem cell-like properties and tumorigenesis [2]. In gastric carcinoma, high Slc17a9 expression was associated with poor overall and recurrence-free survival [3]. In non-small cell lung cancer, Slc17a9 up-regulation was correlated with overall survival, and its knockdown inhibited cell proliferation and ATP levels [4]. In hepatocellular carcinoma, high Slc17a9 expression was related to poor prognosis [6,7]. In colorectal cancer, Slc17a9 overexpression was associated with advanced tumor stages and poor survival, and it was an independent prognostic predictor [9].
In conclusion, Slc17a9 plays a crucial role in regulating cell viability, as well as in the development and progression of multiple cancers. Studies on Slc17a9, especially through loss-of-function experiments in cell lines, have provided valuable insights into its functions in disease processes, potentially offering new targets for cancer diagnosis and treatment.
References:
1. Li, Weiquan, Xu, Ning, Meng, Xiangui, Xiao, Wen, Zhang, Xiaoping. 2022. SLC17A9-PTHLH-EMT axis promotes proliferation and invasion of clear renal cell carcinoma. In iScience, 26, 105764. doi:10.1016/j.isci.2022.105764. https://pubmed.ncbi.nlm.nih.gov/36590170/
2. Li, Huizi, Liu, Jin, Lai, Jie, Zhang, Tong, Gu, Qiuping. 2024. The HHEX-ABI2/SLC17A9 axis induces cancer stem cell-like properties and tumorigenesis in HCC. In Journal of translational medicine, 22, 537. doi:10.1186/s12967-024-05324-2. https://pubmed.ncbi.nlm.nih.gov/38844969/
3. Li, Junqing, Su, Taiqiang, Yang, Liang, Zhang, Changhua, He, Yulong. 2019. High SLC17A9 expression correlates with poor survival in gastric carcinoma. In Future oncology (London, England), 15, 4155-4166. doi:10.2217/fon-2019-0283. https://pubmed.ncbi.nlm.nih.gov/31799885/
4. Gao, Yan, Chen, Yijia, Liu, Min, Ke, Changbin, Pei, Zhijun. 2023. SLC17A9 as a prognostic biomarker correlated with immune infiltrates in human non-small cell lung cancer. In American journal of cancer research, 13, 3963-3982. doi:. https://pubmed.ncbi.nlm.nih.gov/37818081/
5. Huang, Peng, Cao, Qi, Xu, Mengnan, Dong, Xian-Ping. 2022. Lysosomal ATP Transporter SLC17A9 Controls Cell Viability via Regulating Cathepsin D. In Cells, 11, . doi:10.3390/cells11050887. https://pubmed.ncbi.nlm.nih.gov/35269509/
6. Wu, Jingdong, Yang, Yongfei, Song, Jiansheng. 2020. Expression of SLC17A9 in hepatocellular carcinoma and its clinical significance. In Oncology letters, 20, 182. doi:10.3892/ol.2020.12043. https://pubmed.ncbi.nlm.nih.gov/32934749/
7. Kui, Xue-Yan, Gao, Yan, Liu, Xu-Sheng, Zhang, Yao-Hua, Pei, Zhi-Jun. 2022. Comprehensive Analysis of SLC17A9 and Its Prognostic Value in Hepatocellular Carcinoma. In Frontiers in oncology, 12, 809847. doi:10.3389/fonc.2022.809847. https://pubmed.ncbi.nlm.nih.gov/35957868/
8. Inoue, Asako, Nakao-Kuroishi, Kayoko, Kometani-Gunjigake, Kaori, Kokabu, Shoichiro, Kawamoto, Tatsuo. 2020. VNUT/SLC17A9, a vesicular nucleotide transporter, regulates osteoblast differentiation. In FEBS open bio, 10, 1612-1623. doi:10.1002/2211-5463.12918. https://pubmed.ncbi.nlm.nih.gov/32592329/
9. Yang, Liang, Chen, Zhihui, Xiong, Weixin, Song, Xinming, Liu, Jia. 2018. High expression of SLC17A9 correlates with poor prognosis in colorectal cancer. In Human pathology, 84, 62-70. doi:10.1016/j.humpath.2018.09.002. https://pubmed.ncbi.nlm.nih.gov/30236596/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。